Standard BioTools Inc. Amortization of Debt Discount (Premium)
Standard BioTools Inc. (LAB) reported Amortization of Debt Discount (Premium) of $0 for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2014-03-12
- Standard BioTools Inc. amortization of debt discount (premium) for the quarter ending 2012-12-31 was $0.00, a 100.00% decline year-over-year.
- Standard BioTools Inc. amortization of debt discount (premium) for the quarter ending 2012-09-30 was $9.00K, a 71.88% decline year-over-year.
- Standard BioTools Inc. amortization of debt discount (premium) for the quarter ending 2012-06-30 was $20.00K, a 45.95% decline year-over-year.
- Standard BioTools Inc. amortization of debt discount (premium) for the quarter ending 2012-03-31 was $23.00K, a 72.94% decline year-over-year.
- Standard BioTools Inc. amortization of debt discount (premium) for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- Standard BioTools Inc. amortization of debt discount (premium) for fiscal 2012 was $52.00K, a 71.43% decline from fiscal 2011.
- Standard BioTools Inc. amortization of debt discount (premium) for fiscal 2011 was $182.00K, a 50.00% decline from fiscal 2010.
- Standard BioTools Inc. amortization of debt discount (premium) for fiscal 2010 was $364.00K, a 18.18% increase from fiscal 2009.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-03-12 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-12 | $9.00K derived: sum of 2 quarters · filed 2014-03-12 | $29.00K derived: sum of 3 quarters · filed 2014-03-12 | $52.00K 10-K · filed 2014-03-12 |
| 2012-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $29.00K derived: sum of 2 quarters · filed 2012-11-09 | $52.00K 10-Q · filed 2012-11-09 | $80.00K derived: sum of 4 quarters · filed 2014-03-12 |
| 2012-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | $43.00K 10-Q · filed 2012-08-14 | $71.00K derived: sum of 3 quarters · filed 2014-03-12 | $103.00K derived: sum of 4 quarters · filed 2014-03-12 |
| 2012-03-31 | $23.00K 10-Q · filed 2012-05-15 | $51.00K derived: sum of 2 quarters · filed 2014-03-12 | $83.00K derived: sum of 3 quarters · filed 2014-03-12 | $120.00K derived: sum of 4 quarters · filed 2014-03-12 |
| 2011-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-12 | $60.00K derived: sum of 2 quarters · filed 2014-03-12 | $97.00K derived: sum of 3 quarters · filed 2014-03-12 | $182.00K 10-K · filed 2014-03-12 |
| 2011-09-30 | $32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $69.00K derived: sum of 2 quarters · filed 2012-11-09 | $154.00K 10-Q · filed 2012-11-09 | $244.00K derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-06-30 | $37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | $122.00K 10-Q · filed 2012-08-14 | $212.00K derived: sum of 3 quarters · filed 2013-03-12 | $300.00K derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-03-31 | $85.00K 10-Q · filed 2012-05-15 | $175.00K derived: sum of 2 quarters · filed 2013-03-12 | $263.00K derived: sum of 3 quarters · filed 2013-03-12 | |
| 2010-12-31 | $90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $178.00K derived: sum of 2 quarters · filed 2013-03-12 | $364.00K 10-K · filed 2013-03-12 | |
| 2010-09-30 | $88.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $274.00K 10-Q · filed 2011-11-14 | ||
| 2010-06-30 | $186.00K 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | $308.00K 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |